Mark Iwicki

Mr. Iwicki has 25 years of experience as a pharmaceutical industry leader across multiple therapeutic areas. He has extensive experience building businesses and launching products. Prior to joining Kala, Mr. Iwicki was President and Chief Executive Officer of Civitas Therapeutics, which was acquired by Acorda Therapeutics. Previously Mr. Iwicki was CEO of Blend Therapeutics and CEO of Sunovion Pharmaceuticals. At Sepracor, Mr. Iwicki served as Chief Commercial Officer for the company, launching three products and managing all aspects of the company’s portfolio. Prior to joining Sepracor, he was VP and Head of the cardiovascular business unit at Novartis Pharmaceuticals. He began his career with sales and management positions at Merck and Astra Merck.